ADRX — ADARx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1802369 ·
Last close
$18.25
Market Cap
—
52W High
$23.21
52W Low
$17.85
ADV30
1,567,617
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 746,000 | — | -29,891,000 | -25,759,000 | 456,332,000 | 58,484,000 | 707,384,000 |
| Mar 2026 | 2,140,000 | — | -27,056,000 | -22,667,000 | 482,558,000 | 63,858,000 | 708,290,000 |
| Dec 2025 | — | — | — | — | 507,655,000 | 66,517,000 | 709,910,000 |
| Jun 2025 | 208,000 | — | -21,122,000 | -18,093,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$250,868,000
Investing CF
$-207,501,000
Financing CF
$91,000
CapEx
$-1,933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-269,125,000
Inventory
—
Receivables
—
ST Investments
$368,768,000
EBIT TTM
$-95,957,000
Pretax Income TTM
$-82,070,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,449,000 | -88,365,000 | -73,088,000 | 507,655,000 | 709,910,000 | -202,255,000 | 262,288,000 |
| Dec 2024 | 0 | -58,233,000 | -46,360,000 | 233,454,000 | 370,599,000 | -137,145,000 | -48,563,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.02T | $1142.85 | — |
| JNJ | JOHNSON & JOHNSON | $617.01B | $256.03 | — |
| ABBV | AbbVie Inc. | $464.43B | $262.82 | — |
| MRK | Merck & Co., Inc. | $356.01B | $144.30 | — |
| NVS | NOVARTIS AG | $268.00B | $141.00 | — |
News headlines (Yahoo Finance, 1h cache)
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
2026-10-01 20:15 · Yahoo
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
2026-09-28 03:10 · Yahoo
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
2026-09-24 23:33 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-09-29 21:43:23 | 2026-09-28 | George Simeon | Dir, 10% | P - Purchase | 17 | 1600000 | 27200000 |
| 2026-09-30 17:29:36 | 2026-09-28 | Chimovits Erez | Dir | P - Purchase | 17 | 61516 | 1045772 |
| 2026-09-29 21:45:43 | 2026-09-28 | Sr One Capital Management, LLC | 10% | P - Purchase | 17 | 1600000 | 27200000 |
| 2026-09-30 17:23:22 | 2026-09-28 | Orbimed Advisors LLC | Dir, 10% | P - Purchase | 17 | 950000 | 16150000 |
| 2026-09-30 17:25:39 | 2026-09-28 | Gordon Carl L | Dir, 10% | P - Purchase | 17 | 950000 | 16150000 |